Expert Insight Into:
Differential Diagnosis of Suspected Multiple Sclerosis: A Consensus Approach
Based on the Article:
Differential Diagnosis of Suspected Multiple Sclerosis: A Consensus Approach. Mult Scler. 2008;14:1157-1174.
(Course MS02.01)
Published on August 12, 2009 Article Review
Medical Writer: Nicole M. Avena, PhD
Expert Faculty: Robert P. Lisak, MD, FAAN, FRCP
Medical Writer: Nicole M. Avena, PhD
Expert Faculty: Robert P. Lisak, MD, FAAN, FRCP
Click here to view our current activities in Neurology.
Dr. Robert Lisak reviews new guidelines for MS differential diagnosis as determined by a panel of experts in the field of demyelinating disease. These guidelines can help practitioners exclude potential alternatives to an MS diagnosis, diagnose clinically isolated syndromes when MS is suspected, and differentiate between MS and non-MS idiopathic inflammatory demyelinating disease.
Robert P. Lisak, MD, FAAN, FRCP
- Parker Webber Chair in Neurology
- Professor and Chair of Neurology
- Professor of Immunology and Microbiology
- Wayne State University School of Medicine
- Detroit, MI
Tracy M. DeAngelis, MD, is a consultant for Bayer and Teva Neuroscience.
Suhayl Dhib-Jalbut, MD, has received grant/research support from Bayer, Serono and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience; and is on the speakers bureau for Bayer and Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP, has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Fred D. Lublin, MD, has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Aaron E. Miller, MD, has received grant/research support from Acorda Therapeutics, Biogen Idec, Genzyme, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Acorda Therapeutics, Bayer, Biogen Idec, EMD Serono, Genentech, Inc, GlaxoSmithKline, Sanofi-Aventis, and Teva Neuroscience; and is on the speakers bureau for Bayer, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
Available for CME/CE:
Physicians
Publish Date: Aug 12, 2009 Termination Date: Aug 12, 2010Nurses
Publish Date: Aug 12, 2009 Termination Date: Aug 12, 2010Pharmacists
Publish Date: Aug 12, 2009 Termination Date: Aug 12, 2010Estimated time for completion of this activity:
CNE: 30.60 minutes
CPE: 1.0 hour
Target Audience
This activity is designed for neurologists and other clinicians who specialize in and care for patients with multiple sclerosis.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with multiple sclerosis.
Learning Objective (s)
- Incorporate newly defined specific "red flags” differentiating MS from other disorders in making a diagnosis in patients with clinical symptoms suggestive of MS.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
This activity is approved for 0.51 nursing contact hour(s).
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.
You must complete two article reviews to receive a certificate of 1 or more contact hours. Your statement of credit will be available once you have completed the posttest and evaluation associated with each article review. Projects In Knowledge will record your participation in each article review in your CE tracker.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Program Number assigned to this activity is 052-000-09-061-H01-P.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Robert P. Lisak, MD, FAAN, FRCP has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nicole M. Avena, PhD has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Anne H. Cross, MD has received grant/research support from Acorda Therapeutics, Genentech, Inc and Sanofi-Aventis; is on the speakers bureau for Bayer Healthcare and Teva Neuroscience; and is on the advisory boards of Bayer Healthcare, Biogen Idec, BioMS Medical, and Eli Lilly and Company.
Tracy M. DeAngelis, MD is a consultant for Bayer and Teva Neuroscience.
Suhayl Dhib-Jalbut, MD has received grant/research support from Bayer, Serono and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience; and is on the speakers bureau for Bayer and Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Fred D. Lublin, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Aaron E. Miller, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genzyme, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Acorda Therapeutics, Bayer, Biogen Idec, EMD Serono, Genentech, Inc, GlaxoSmithKline, Sanofi-Aventis, and Teva Neuroscience; and is on the speakers bureau for Bayer, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Aug 12, 2009 Termination Date: Aug 12, 2010Nurses
Publish Date: Aug 12, 2009 Termination Date: Aug 12, 2010Pharmacists
Publish Date: Aug 12, 2009 Termination Date: Aug 12, 2010Estimated time for completion of this activity:
CNE: 30.60 minutes
CPE: 1.0 hour
Target Audience
This activity is designed for neurologists and other clinicians who specialize in and care for patients with multiple sclerosis.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with multiple sclerosis.
Learning Objective (s)
- Incorporate newly defined specific "red flags” differentiating MS from other disorders in making a diagnosis in patients with clinical symptoms suggestive of MS.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
This activity is approved for 0.51 nursing contact hour(s).
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.
You must complete two article reviews to receive a certificate of 1 or more contact hours. Your statement of credit will be available once you have completed the posttest and evaluation associated with each article review. Projects In Knowledge will record your participation in each article review in your CE tracker.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Program Number assigned to this activity is 052-000-09-061-H01-P.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Robert P. Lisak, MD, FAAN, FRCP has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nicole M. Avena, PhD has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Anne H. Cross, MD has received grant/research support from Acorda Therapeutics, Genentech, Inc and Sanofi-Aventis; is on the speakers bureau for Bayer Healthcare and Teva Neuroscience; and is on the advisory boards of Bayer Healthcare, Biogen Idec, BioMS Medical, and Eli Lilly and Company.
Tracy M. DeAngelis, MD is a consultant for Bayer and Teva Neuroscience.
Suhayl Dhib-Jalbut, MD has received grant/research support from Bayer, Serono and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience; and is on the speakers bureau for Bayer and Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Fred D. Lublin, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Aaron E. Miller, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genzyme, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Acorda Therapeutics, Bayer, Biogen Idec, EMD Serono, Genentech, Inc, GlaxoSmithKline, Sanofi-Aventis, and Teva Neuroscience; and is on the speakers bureau for Bayer, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|



